Bristol-Myers Squibb Co. (BMY)

62.25
NYSE : Health Technology
Prev Close 61.75
Day Low/High 61.75 / 62.62
52 Wk Low/High 49.96 / 70.05
Avg Volume 5.49M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 100.77B
EPS 0.60
P/E Ratio 257.29
Div & Yield 1.60 (2.62%)
Bristol-Myers Squibb Announces Dividend Increase

Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.

CheckMate -078, A Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial With Predominantly Chinese Patients, Stopped Early For Demonstrating Superior Overall Survival

CheckMate -078, A Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial With Predominantly Chinese Patients, Stopped Early For Demonstrating Superior Overall Survival

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Phase 3 study CheckMate -078, evaluating Opdivo (nivolumab) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer...

Bristol-Myers Squibb To Take Part At The Citi 2017 Global Healthcare Conference

Bristol-Myers Squibb To Take Part At The Citi 2017 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2017 Global Healthcare Conference on Wednesday, December 6, 2017, in New York.

Bristol-Myers Squibb To Present New Data Across A Broad Range Of Blood Cancers At The 59th Annual Meeting & Exposition Of The American Society Of Hematology

Bristol-Myers Squibb To Present New Data Across A Broad Range Of Blood Cancers At The 59th Annual Meeting & Exposition Of The American Society Of Hematology

Bristol-Myers Squibb Company (NYSE: BMY) announced today 33 presentations from Company-sponsored studies, collaborations and investigator-sponsored research evaluating Opdivo (nivolumab), Sprycel (dasatinib) and...

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To Neutrolis, Remora Therapeutics

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To Neutrolis, Remora Therapeutics

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the...

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) Plus Yervoy (ipilimumab) In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) Plus Yervoy (ipilimumab) In Intermediate- And Poor-Risk Patients With Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) plus...

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

Bristol-Myers Squibb To Take Part In Evercore ISI Biopharma Conference

Bristol-Myers Squibb To Take Part In Evercore ISI Biopharma Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI Biopharma Conference on Wednesday, November 29, 2017, in Boston.

Medtronic's Strong Q1 Helps Send Healthcare Stocks Higher

Medtronic's Strong Q1 Helps Send Healthcare Stocks Higher

The Health Care SPDR ETF (XLV) was rising nearly 1% in afternoon trading on Tuesday, boosted in part, by solid results from medical equipment company Medtronic.

Encouraging Response Observed With Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, In Heavily Pre-Treated Patients With Advanced Cancers In Phase 1/2a Study CA017-003

Encouraging Response Observed With Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, In Heavily Pre-Treated Patients With Advanced Cancers In Phase 1/2a Study CA017-003

Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results for Opdivo (nivolumab) plus BMS-986205, a selective, once-daily oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor from the ongoing Phase 1/2a...

Bristol-Myers Squibb To Take Part In Jefferies London Healthcare Conference

Bristol-Myers Squibb To Take Part In Jefferies London Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Jefferies London Healthcare Conference on Wednesday, November 15, 2017, in London.

Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels In Intermediate- And Poor-Risk Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels In Intermediate- And Poor-Risk Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) announced today results from a new exploratory analysis of the phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus the standard of care,...

Bristol-Myers Squibb To Highlight Clinical And Translational Research At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Bristol-Myers Squibb To Highlight Clinical And Translational Research At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 23 abstracts spanning its expansive oncology research program will be presented at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual Meeting from...

Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)

Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)

Bristol-Myers Squibb Company (NYSE:BMY) announced today a three-year overall survival (OS) update from its phase 3 CheckMate -025 study, evaluating patients treated with Opdivo (nivolumab) versus everolimus in...

Lung Love Walk Houston Participants Welcomed Eric Stonestreet, Spokesperson For Bristol-Myers Squibb's Ready. Raise. Rise. Campaign, At The Waterworks At Buffalo Bayou Park On Saturday, Nov. 4, 2017 In Houston. (Anthony Rathbun/AP Images For Bristol-Myers Squibb)

Lung Love Walk Houston Participants Welcomed Eric Stonestreet, Spokesperson For Bristol-Myers Squibb's Ready. Raise. Rise. Campaign, At The Waterworks At Buffalo Bayou Park On Saturday, Nov. 4, 2017 In Houston. (Anthony Rathbun/AP Images For Bristol-Myers Squibb)

Eric Stonestreet of TV's "Modern Family" made a surprise appearance at Lung Cancer Alliance's Lung Love Walk Houston as part of Bristol-Myers Squibb's Ready.

Bristol-Myers Squibb To Showcase Company's Progress In Researching Personalized Medicine For The Potential Treatment Of Autoimmune Diseases At 2017 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb To Showcase Company's Progress In Researching Personalized Medicine For The Potential Treatment Of Autoimmune Diseases At 2017 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today confirmed that 34 abstracts related to ORENCIA ® (abatacept) and the Company's immunoscience pipeline will be presented at the 2017 American College of Rheumatology...

Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship In Support Of Promising Biotech Companies In New York

Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship In Support Of Promising Biotech Companies In New York

Bristol-Myers Squibb Company (NYSE:BMY) and BioLabs, a network of shared lab facilities for high-potential life-science startups, located in the nation's key biotech innovation clusters, today announced Bristol-Myers...

Bristol-Myers Squibb Bulls Take a Short Break

Bristol-Myers Squibb Bulls Take a Short Break

There is strong support just below the market for drug giant.

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

It depends on which aisle of the stock market you're on.

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) For Treatment Of Patients With Resected High-Risk Advanced Melanoma

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo (nivolumab) For Treatment Of Patients With Resected High-Risk Advanced Melanoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) to...

Where Have All the Buyers Gone?; Safety Dance -- Jim Cramer's Top Thoughts

Where Have All the Buyers Gone?; Safety Dance -- Jim Cramer's Top Thoughts

Cramer reflects on where all the buyers have gotten to and also discusses the stock market's safety dance.

Big Opportunities to Buy Stocks Have Secretly Emerged

Big Opportunities to Buy Stocks Have Secretly Emerged

The stock market has had a wild week. Some interesting opportunities may have finally emerged.

Rethinking Risk and Reward: Cramer's 'Mad Money' Recap (Thursday 10/26/17)

Rethinking Risk and Reward: Cramer's 'Mad Money' Recap (Thursday 10/26/17)

Jim Cramer says that in this market, what we thought were safe stocks are now risky, and the dangerous ones have become the safer bets.

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Alexion Pharmaceuticals, Bristol-Myers Squibb and Celgene were among the healthcare firms that unveiled quarterly numbers on Oct. 26.

Cramer: Stock Market's 'Safety Dance' Has Reversed

Cramer: Stock Market's 'Safety Dance' Has Reversed

What was dangerous is now safe, what was safe is now risky.

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Celgene's Stock Is Getting Absolutely Torched -- Don't Panic, Yet

Shares of Celgene are down more than 30% so far this month and almost 20% Thursday as the company cuts full-year and 2020 guidance.

Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.

TheStreet Quant Rating: C+ (Hold)